Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Trial of Human CD19 Targeted T Cells Injection for Subjects With Relapsed and Refractory CD19-positive Diffuse Large B-cell Lymphoma and Follicular Lymphoma

NCT03720457 is registered in ClinicalTrials.gov with Hrain Biotechnology Co., Ltd. as lead sponsor.

NCT NCT03720457
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03720457 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Trial of Human CD19 Targeted T Cells Injection for Subjects With Relapsed and Refractory CD19-positive Diffuse Large B-cell Lymphoma and Follicular Lymphoma
Lead sponsor
Hrain Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
November 13, 2018
Completion date
October 31, 2023
Enrollment
18 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cd19-positive, diffuse large b-cell lymphoma, follicular lymphoma